News Coverage from EULAR 2024: Benefits of Early Belimumab Intervention in SLE, with Karen Costenbader, MD
In an interview with HCPLive,Karen Costenbader, MD, director of the Lupus Program at Brigham and Women’s Hospital, gives an overview of 2 analyses that demonstrated treatment with belimumab reduces flares and increases Systemic Lupus Erythematosus Responder Index 4 (SRI-4) response rates among patients with early active systemic lupus erythematosus (SLE). Findings were presented at the 2024 European Congress of Rheumatology (EULAR) conference.
The recent secondary analyses of data from 5 major belimumab trials have provided significant insights. These outcomes, collected during the trials but not previously analyzed in this manner, are considered robust despite being post-hoc analyses.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
